NCT02675231: A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

NCT02675231
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must have received at least 2 HER2-directed therapies for advanced disease; Patient must have received trastuzumab emtansine (Kadcyla/T-DM1) & a taxane in any disease setting
Exclusions: Patients with known central nervous system (CNS) metastases that are untreated, symptomatic, or require steroids to control symptoms; Patients who received prior treatment with any CDK 4/6 inhibitor (e.g. Ibrance/palbociclib, Verzenio/abemaciclib, Kisqali/ribociclib)
https://ClinicalTrials.gov/show/NCT02675231

Comments are closed.

Up ↑